ImmunoCellular (IMUC) and Formatech, a therapeutics company, have agreed to join forces for the manufacture of ICT-121, a cancer stem cell vaccine for an upcoming clinical trial.
ICT-121 is a candidate drug that is known to target cancer stem cells and may also have applicability to multiple types of cancer.
The Phase I clinical trial of ICT-121 will target glioblastoma, and is expected to begin early in 2010.
Under the agreement Formatech will prepare the vials of cancer vaccine for the clinical trial, under a GMP (Good Manufacturing Practices) environment.
IMUC president and CEO Manish Singh said that ICT-121 has shown its ability in preclinical studies to target and destroy cancer stem cells present in brain tumours.
"We are excited to initiate this trial in the coming months with the ultimate goal of being able to someday offer to patients a safer and more effective treatment alternative than the current standard of care," Singh said.
ICT-121 has yet to get clearance from the US Food and Drug Administration.